Independence Blue Cross (Independence) recently announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023
Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies
Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries
Optum Frontier Therapies Centers of Excellence (COEs) consist of dedicated teams focused on cell and gene therapy, rare disease drugs and digital therapeutics
Alnylam® Pharmaceuticals selected PantherRx Rare and Orsini Specialty Pharmacy as limited distribution partners for OXLUMO™ (lumasiran). OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that […]
OutcomeRx focuses on engaging with biotech companies to think through, structure, and manage value-based agreements
Cell and gene therapies are revolutionizing the field of medicine by offering life-changing benefits to people with rare diseases and cancers
Payers are planning for an increasing number of gene therapies being approved by developing new coverage programs